News

  • ASCOT and REMAP-CAP awarded nearly $4 million to combine platforms to test new therapeutics to treat COVID-19

    ASCOT and REMAP-CAP have been awarded $3,997,914 by the Australian Government through the Medical Research Future Fund (MRFF) in a joint proposal t...
  • ASCOT closes the Antiviral Treatment Domain

    On Thursday, 11 August 2022, the ASCOT Trial Steering Committee (TSC), with support from the Antiviral Domain-Specific Working Group (DSWG), made t...
  • ASCOT closes the Anticoagulation Treatment Domain

    On Thursday, 7 April 2022, the ASCOT Trial Steering Committee (TSC), with support from the Anticoagulation Domain-Specific Working Group (DSWG), ma...
  • COVID-19 clinical trials disproportionately run out of high-income countries research shows

    New research has shown that COVID-19 clinical trials are being disproportionately run out of high-income countries.
  • ASCOT randomises 1,000th patient

    Australasian COVID-19 Trial (ASCOT) reached an important milestone on Tuesday, 21 September 2021, randomising the 1,000th patient into the study. T...
  • ASCOT removes aspirin from trial

    On the 22 July 2021, the ASCOT International Trial Steering Committee (ITSC) made the decision to cease patient enrolment into aspirin-containing a...
  • Oxford is trialling Ivermectin - the path to this point has been rocky, why?

    By Associate Professor Justin Denholm, Principal Investigator on ASCOT The PRINCIPLE trial recently announced that their ongoing platform will now ...
  • COVID-19 – The Israel experience

    By Dr Neta Petersiel, Clinical Research Fellow for ASCOT  The past 18 months often feel like a weird dream, our reality perhaps forever changed by ...
  • National approach to pandemic research needed

    Australia should follow the examples of the UK and parts of the US and establish a national, coordinated approach for randomised controlled trials...
  • Infection and Immunity – Evidence Explained podcast: COVID-19 treatments part one, the Australian experience

    In the latest episode of Doherty Institute's Infection and Immunity - Evidence Explained podcast, Associate Professor Steven Tong, Infectious Disea...
  • Nafamostat for treatment of COVID-19

    As COVID-19 is a new disease resulting in an unprecedented global healthcare burden, there have been a very large number of drugs rapidly escalated...
  • AustralaSian COVID-19 Trial opens in India

    The AustralaSian COVID-19 Trial (ASCOT) has been expanded into India, with the first patients recruited last week to the first two sites, Christi...